A Study to Investigate the Safety, Tolerability, Immunogenicity, and Pharmacodynamics of VXX-401 Compared With Placebo in Adult Participants
Study Details
Study Description
Brief Summary
This first-in-human (FIH) study of VXX-401, an anti-PCSK9 peptide-based immunotherapeutic candidate, is designed to assess the safety, tolerability, immunogenicity, and pharmacodynamics (PD) of VXX-401 and to determine an optimal dose regimen for LDL-C lowering in subsequent clinical trials.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Detailed Description
This is multisite, randomized, double-blind, placebo-controlled, multidose regimen, phase 1, first-in-human study of VXX-401, a synthetic peptide-based active immunotherapy candidate for preventing and treating hypercholesterolemia. The study will include Screening, Treatment, and Follow-up Periods. This study will enroll participants who are naïve to statin use. Each cohort is planned to randomize approximately 12 participants to receive priming doses of VXX-401 or placebo in a 3:1 ratio. This study will have 4 dosing cohorts, A - D. It is planned to test up to 4 dose regimens of VXX-401 or placebo, administered by IM injection into the deltoid muscle. All eligible participants will receive a priming regimen at Week 0 (Baseline, Day 1), Week 4, and Week 12, in Cohorts A and C, and additionally at Week 8 in Cohorts B and D. The last dose administration will be at Week 12. There is one dose escalation from 100 μg to 300 μg between cohorts B and C. All participants will be followed through Week 30 (EOS).
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: VXX-401 Cohort A VXX-401 100mcg administered by intramuscular (IM) injection at Week 0, Week 4, and Week 12 |
Drug: VXX-401
A synthetic PCSK9 peptide-based immunotherapy
|
| Experimental: VXX-401 Cohort B VXX-401 100mcg administered by intramuscular (IM) injection at Week 0, Week 4, Week 8 and Week 12 |
Drug: VXX-401
A synthetic PCSK9 peptide-based immunotherapy
|
| Experimental: VXX-401 Cohort C VXX-401 300mcg administered by intramuscular (IM) injection at Week 0, Week 4, and Week 12 |
Drug: VXX-401
A synthetic PCSK9 peptide-based immunotherapy
|
| Experimental: VXX-401 Cohort D VXX-401 300mcg administered by intramuscular (IM) injection at Week 0, Week 4, Week 8 and Week 12 |
Drug: VXX-401
A synthetic PCSK9 peptide-based immunotherapy
|
| Placebo Comparator: Placebo Cohort A and C Placebo administered by intramuscular (IM) injection at Week 0, Week 4, and Week 12 |
Biological: Placebo
Normal saline
|
| Placebo Comparator: Placebo Cohort B and D Placebo administered by intramuscular (IM) injection at Week 0, Week 4, Week 8 and Week 12 |
Biological: Placebo
Normal saline
|
Outcome Measures
Primary Outcome Measures
- Frequency of adverse events [30 weeks]
Safety and tolerability: rates of adverse events (AEs), medically attended adverse events (MAAEs), local (injection site) and systemic (generalized) reactions (i.e., reactogenicity), clinical laboratory assessments (e.g., chemistry, hematology, urinalysis, lipid profile), serum cytokine release, vital signs, physical examinations, and electrocardiograms (ECGs) through the end of the study.
- Immunogenicity [Baseline to Week 16, 20, 24, and 30]
Immunogenicity will be measured by serum anti-PCSK9 antibody titers
- Immunogenicity [Baseline to Week 16, 20, 24, and 30]
Seroconversion two-fold and four-fold from baseline
Secondary Outcome Measures
- Evaluation of low-density lipoprotein-cholesterol (LDL-C) reduction [Baseline to Week 16, 20, 24, and 30]
Percent change from baseline in serum LDL-C concentration
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Male or female participants aged 18 to 75 years old, inclusive, at time of informed consent.
-
LDL-C level = 2.59 mmol/L - 4.89mmol/L
-
Body mass index between 18 and 35 kg/m2, inclusive at Screening, and with a minimum weight of 50 kg.
-
Male participants and their partners of childbearing potential must commit to the use of highly effective contraceptives for the study duration and for at least 12 weeks after the last dose. Men must refrain from donating sperm during this same period.
-
Female participants must be of nonchildbearing potential, or, for women of childbearing potential, must be willing to practice at least one form of highly effective contraception throughout the duration of the study and for at least 24 weeks following the last dose. Female participants must refrain from donating reproductive tissue during this same period.
Exclusion Criteria:
-
Subjects considered high risk or very high risk for ASCVD and requiring immediate treatment with LLT according to the clinical judgement of the investigator.
-
History of confirmed anergy (i.e., not able to mount an immunological response) or history of immunization failure in the 5 years prior to the Screening Visit.
-
Presence of fever >38°C or other signs or symptoms of acute disease within 1 week before the Screening and/or Visit 1; Screening and/or Visit 1 may be rescheduled at the discretion of the Investigator but must occur within the 4-week window.
-
Known disturbance of coagulation or medication (see prohibited medications criterion below); bleeding disorder (e.g., factor deficiency, coagulopathy, or platelet disorder), or prior history of significant bleeding or bruising following IM injections or venipuncture.
-
Triglycerides > 500 mg/dL.
-
Has a history of clinically significant medical disorder or psychiatric conditions, which in the opinion of the investigator may compromise the participant's safety and ability to comply with study procedures or abide by study restrictions.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Emeritus Research | Sydney | New South Wales | Australia | |
| 2 | University of the Sunshine Coast (USC) | Morayfield | Queensland | Australia | |
| 3 | Emeritus Research | Melbourne | Victoria | Australia |
Sponsors and Collaborators
- Vaxxinity, Inc.
- Novotech (Australia) Pty Limited
Investigators
- Study Director: Carlos Chirinos-Rojas, Vaxxinity, Inc.
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- VXX-401-101